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S100B, a calcium-dependent protein produced by astroglial cells in the 
central nervous system (CNS) and by chondrocytes, functions as both a neurotrophin 
and neurotoxin.   It has a half-life in the systemic circulation of approximately six 
hours.  We examined whether serum levels of S100B would be predictive of 
intracranial injury (ICI) in children, as detected by cranial computed tomography 
(CT), in children with closed head trauma (CHT).   In addition, we evaluated the 
effect of long bone fractures on the level of S100B in children with both CHT and 
extracranial injuries such as long bone fractures.  One hundred fifty-two children, 
who presented to the Pediatric Emergency Department of Yale -New Haven 
Children's Hospital, within six hours of accidental CHT, and required CT to exclude 
ICI, were prospectively enrolled.  After informed consent from a caregiver, samples 
were obtained by venipuncture and analyzed for a quantitative serum level of S100B.   
Of the 152 children enrolled in this study, 24 had an ICI.  Mean S100B levels 
were significantly greater in children with ICI (0.212 µg/L vs. 0.084 µg/L; p<0.001), 
in children with long bone fractures (0.220 µg/L vs. 0.083 µg/L; p<0.001), and in 
children who were non-white (0.127 µg/L vs. 0.081 µg/L; p=0.03).  Sixty-two 
percent of children with ICI had venipuncture performed more than 120 minutes 
after head injury.  After controlling for time of venipuncture, fractures, and race, 
mean S100B levels were still greater in children with ICI (0.409 µg/L vs. 0.118  
   
 
µg/L; p<0.001).  The discriminatory value of S100B to detect ICI, as determined by 
the area under the receiver operator characteristics (ROC) curve, was 0.67.  Further 
study of S100B is necessary to determine whether this biochemical marker could 
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 Head trauma is a major cause of morbidity and mortality in children.  Each 
year over 400,000 children under the age of 14 years present with closed head 
trauma (CHT) to Emergency Departments across the United States (1).  Children less 
than 4 years of age are twice as likely to experience CHT as any other age group.  In 
children under the age of one year, head injury is the leading cause of death (2). 
Since no serum diagnostic marker exists to distinguish which children have 
intracranial injuries after CHT, the majority of symptomatic children who present 
with a head injury will undergo computed tomography (CT) to exclude intracranial 
injury (ICI).  Despite the presence of such post-traumatic complaints as nausea, 
headache, vomiting, and loss of consciousness at the time of admission to the 
Emergency Department, most children with such symptoms and CHT will not have 
ICI (3).  Thus, we wished to determine whether serum S100B levels could predict 
the presence of ICI by CT, in children who suffer CHT.   
Children with CHT who undergo a CT scan sometimes require sedation to 
produce a more precise image of the brain. Yet both sedation and diagnostic imaging 
carry serious health risks to children.  Adverse sedation events, defined as death and 
permanent neurological injury, are associated with drug overdose and drug 
interactions (4).   Negative outcomes are particularly frequent in hospital settings 
when three or more drugs are employed to sedate a patient.  Furthermore, the lack of 
specific pediatric labeling on medication makes children vulnerable to the possibility  
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of an adverse sedation event; both transcription mistakes and flawed dose dispensing 
occur in the United States with sufficient regularity to raise alarm (4).   In addition to 
the risk of adverse outcome from sedation errors, children are also exposed to a 
significant amount of radiation when undergoing a CT scan.  Although the recent 
development of the faster helical CT scan has reduced the need for sedation in 
pediatric patients, a much higher radiation dose is required (5).  Children are 
significantly more radiosensitive than adults, as their larger numbers of dividing cells 
are most susceptible to radiation induced neoplastic transformation (6). 
More than 600,000 abdominal and head CT examinations are performed 
annually in the United States in children under the age of 15 years.  Approximately 
500 of these patients will eventually develop cancer attributable to the CT radiation 
(7).  Not only is the brain highly radiosensitive, but the risk of brain cancer as a 
result of radiation exposure increases with decreasing age.  Although the 
development of reduced-exposure pediatric CT scanners has been recommended, no 
such machines currently exist. Thus, the majority of symptomatic children who 
present to the Emergency Department with CHT undergo CT, as there is no other 
diagnostic method to evaluate the presence of ICI.  Less than 10% of such scans in 
children will demonstrate ICI (8). 
In order to limit the use of CT imaging, investigators have established clinical 
criteria that may help to predict which patients who arrive at the Emergency 
Department with head injury are at risk for ICI.  Oman et al. studied the sensitivity of  
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conditions such as loss of consciousness, skull fracture, neurological deficit, 
persistent vomiting, and abnormal behavior, to determine which patients with head 
trauma would likely have ICI (9).  Thus, 1666 children with head trauma who 
underwent CT imaging in twenty-one participating Emergency Departments were 
examined.  Of this sample, 8% (138) of patients had ICI as detected by CT.  The 
independent use of clinical criteria, such as loss of consciousness and abnormal 
behavior, correctly identified ICI in 136 out of 138 patients. Therefore, the use of 
clinical criteria successfully recognized the majority of patients with CHT who were 
at risk for ICI.   
Dunning et al. evaluated a similar clinical decision rule for the management 
of children with CHT in order to limit the number of patients who undergo 
diagnostic imaging. This prospective NEXUS II (National Emergency X-
Radiography Utilization Study) cohort study enrolled 22,772 patients less than 16 
years old who presented to ten emergency departments across England with CHT 
(10).  CT scans were ordered for children with any of the following conditions: 
witnessed loss of consciousness, history of amnesia, three or more episodes of 
vomiting, seizure, GCS < 14, signs of basilar skull fracture, a focal neurological 
deficit, or if the mechanism included a motor vehicle crash, high-speed injury, or fall 
greater than 3 meters in height.  Intracranial injuries of four patients were missed 
using this algorithm, demonstrating a sensitivity of 98%, and specificity of 87% (10).  
Validation of this study is required, however, before emergency physicians can  
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confidently apply this algorithm as they assess which children should undergo a CT 
scan for CHT.   
One of the biggest limitations of such clinical decision rules is the type of 
wording and inter-observer reliability of clinical predictors such as headache.  A 
patient who describes his/her headache as ‘severe’ following ICI is perhaps more 
likely to get a CT scan than a patient who fails to further delineate the nature of 
his/her headache.  Sun et al. examined the difference in clinicians' interpretations of 
clinical predictors used to determine whether to obtain a CT scan for a pediatric 
patient with ICI (11).  Although some definitions, such as ‘abnormal mental status’ 
and ‘skull fracture’ were similar between the two studies, the definitions for 
clinically relevant ‘vomiting’ and ‘headache’ were different. Whereas the UC Davis 
study defined ‘vomiting’ as ‘history of vomiting,’ the NEXUS II study defined 
‘vomiting’ as ‘inclusive of recurrent, projectile or forceful emesis after trauma, or 
vomiting associated with altered sensorium.’  In a similar fashion, the UC Davis 
definition of ‘headache’ was much broader than the definition provided by NEXUS 
II.  Sun et al determined that the use of the specific NEXUS II decision instrument 
would have mislabeled a significant number of children with clinically relevant 
intracranial injury as not being at risk for such (11).   Thus, clinical decision rules 
require carefully worded definitions and high inter-observer reliability if they are to 
be utilized appropriately and are one of the limitations of the use of such an 
instrument. 
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Because of the complex issues that clinicians must consider when evaluating 
children for ICI after CHT, we examined the ability of a serum biomarker, S100B, to 
correctly predict which children had ICI after CHT.  The group of S100 calcium 
binding proteins in the human body includes approximately 16 units, each having a 
unique pattern of cellular expression.  The family of proteins was named S100 as a 
result of their solubility in a solution of 100 % saturated ammonium sulfate at neutral 
pH (12).  Furthermore, the S100 genes are situated together on chromosome 1q21.  
Individuals with Down syndrome, epilepsy, and Alzheimer’s disease express higher 
baseline levels of S100B than healthy individuals.  
The S100 proteins consist of dimers, each of which has a subunit composition 
of αα, ββ, or αβ.  S100AA and S100BB (also known as S100B) predominate, and are 
located in different cells throughout the human body.  Whereas S100A is found in 
myocardial cells, acinar cells, renal tubules, and muscle fibers, S100B is 
concentrated primarily in the central nervous system, and to a lesser degree in 
chondrocytes and adipocytes (11).   In the brain, S100B links the variation of 
intracellular calcium levels to alterations in cell function.  S100B regulates neuron 
extension, calcium fluxes, and inhibition of PKC-mediated phosphorylation, 
astrocytosis and axonal proliferation.  S100B seems to be most abundant in glial 
cells, although its presence in other neuronal cells has also been described.   At low 
concentrations S100B promotes neuronal development, survival, and repair (13).  
High extracellular concentrations of S100B, on the other hand, seem to initiate  
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neuronal cell death via both nitric oxide release from astrocytes, and induced 
apoptosis.  Thus, S100B likely functions both as a neurotrophin and a neurotoxin 
after closed head injury, depending on its concentration and the time elapsed since 
the injury occurred (14). 
As a result of its relatively large molecular weight of 20 kDa, S100B is 
normally unable to pass through the brain-blood barrier into the systemic circulation 
(12).  Therefore, its concentration is negligible in the bloodstream of healthy 
individuals.  When the brain-blood barrier is disrupted after ICI, however, serum 
S100B levels rise significantly.  Serum S100B has a half-life of approximately six 
hours, and is readily excreted in urine (15).   Thus, it is imperative to measure serum 
levels of S100B shortly after CHT for it to be useful as a marker for ICI.  An 
inexpensive enzyme-linked immunoassay (ELISA) exists (Can Ag Diagnostics AB, 
Gothenburg, Sweden) that can accurately determine the concentration of serum 
S100B; the cost is approximately $9 per patient. In contrast, each CT scan costs 
approximately $350 and carries the risk of radiation exposure, often combined with 
the risk of sedation.  If serum S100B levels accurately correlate with the presence of 
ICI after CHT, we could determine which children would most likely require a CT 
scan after CHT, prevent exposure to radiation and sedation, and reduce medical 
costs.  
 Over the past ten years, researchers have examined the extent to which serum 
biomarkers, such as S100B, GFAP, IL-6, and NSE, could determine the presence of  
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ICI after CHT in adults.  Results of these studies suggested that S100B might be 
more useful than other biomarkers.  Specifically, S100B levels have been 
demonstrated to be elevated in adults with traumatic brain injury, cerebral infarction, 
spontaneous subarachnoid hemorrhage, intracranial tumors, meningitis, 
hydrocephalus, and spinal cord compression (11,16).  Thus, to evaluate S100B as a 
marker for ICI after CHT, children with a history of brain tumors, hydrocephalus, 
spinal cord injuries, or Down syndrome would be excluded in the patient population 
to be studied.  
 In order to determine the significance of an elevated serum S100B level in 
patients with ICI, however, one must be able to compare it with serum S100B levels 
in patients without brain abnormalities.  Nygaard et al. attempted to define the 
baseline level of serum S100B in healthy adults.  Blood was obtained from 110 
patients between the ages of 20 and 89 years undergoing surgery with spinal 
anesthesia (17).   Exclusion criteria included neurological disease or malignancy. 
They employed a commercially available kit (Sangtec Medical, Bromma, Sweden) 
for the analysis of S100B in serum, and identified the lowest detectible value as 0.2 
µg/L.  In this study S100B was not detected in any patient.  Therefore, Nygaard et al. 
concluded that S100B is normally less than 0.2 µg/L in the serum of healthy adults 
(17).  With the establishment of an adult baseline S100B level, it is reasonable to 
study the relationship between S100B and ICI.  Raabe et al. investigated S100B as a 
serum marker of brain damage after severe traumatic brain injury in adults (18).   
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Venous blood samples were taken at admission and every 12 hours thereafter for 10 
days from 84 patients with severe traumatic brain injury as detected by CT scan.  
S100B values above 0.5 µg/L were considered elevated.  A strong correlation 
between abnormal CT scan results and initial S100B levels above 0.5 µg/L was 
noted.  Furthermore, 39% of patients succumbed to their injuries within 6 months. 
Patients who died had a significantly higher median serum S100B values (2.7 µg/L) 
compared with surviving patients (0.54 µg/L) (17).   In most patients S100B levels 
remained elevated over the course of the first few days after brain injury, irrespective 
of outcome.   Patients with a poor neurological outcome, however, had persistently 
elevated levels of S100B, which may reflect continuing secondary brain injury after 
the initial insult.   Additional studies by Vos et al. demonstrated that serum levels of 
S100B at the time of admission help to predict the extent of ICI in patients with 
severe CHT (19). 
 Ingebrigtsen et al. sought to validate S100B as a biomarker of brain injury 
after mild CHT.  Fifty patients with minor head injuries, normal CT scans, and 
Glasgow Coma Scale (GCS) of 13-15 were enrolled in this prospective study (20).  
Patients underwent MRI scans in order to reveal any subtle intracranial injuries not 
observed by CT.  Blood was drawn at admission, and every hour for 12 hours.  
Elevated S100B levels were detected in 28% of patients. Levels of serum S100B 
were highest immediately after trauma and subsequently declined.  In addition, MRI  
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scans discovered intracranial injuries not previously detected by CT scan in 5 
patients, 4 of whom had high S100B levels (20).   
Pediatric studies have examined the relationship between S100B and ICI in 
children with CHT.  As with adult studies, it is important to determine the baseline 
serum S100B levels in the bloodstream of healthy infants and children.  An inverse 
relationship between age and serum S100B levels was noted by Amer-Whalin et al 
(21).   Infants have significantly higher normal serum S100B level than those of 
either children or adults.  Maschmann et al. reported the serum S100B levels in 66 
healthy neonates as 2.4-3.5 µg/L, which is significantly greater than the mean S100B 
level in adults of 0.2 µg/L (22).  Blood was collected in 12-24 hour intervals over the 
first seven days of life.  Maschmann et al. concluded that amplified protein turnover 
in neuronal cells, combined with increased permeability of the brain-blood barrier in 
infants, leads to the subsequent escape of S100B from the central nervous system. 
Spinella et al. examined the difference between serum S100B in 136 healthy 
children, and 27 children with traumatic brain injury (23).   The mean serum S100B 
level in the control group of children was 0.3 µg/L, and was characterized by an 
expected moderate inverse relationship with age.  Blood was drawn within a mean of 
7 hours after CHT in 27 pediatric patients.  A serum S100B level of 2 µg/L 
demonstrated 86% sensitivity and 95% specificity to predict poor outcome after 6 
months (23).   Although a strong association between high S100B levels and poor  
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outcome was noted, a study with a larger number of patients is required to determine 
whether S100B is indeed an independent predictor of outcome after ICI in children.  
 Similarly, Berger et al. measured the serum concentrations of S100B in 
children after mild, moderate, and severe traumatic brain injury (24).    Forty-five 
children between the ages of 0 and 13 years with closed head injury were enrolled 
prospectively.   Blood was drawn upon arrival to the Emergency Department, and 
every 12 hours for 5 days thereafter.  However, the relationship of the time of injury 
and the time of first blood draw was not mentioned in this study.  No correlation 
between the presence of vomiting, loss of consciousness, or post-traumatic seizure 
and serum S100B levels was demonstrated.  After 12 hours, an abnormally high 
S100B level was noted only in patients with severe head injury. The short half-life of 
S100B would explain why there was no sustained increase of S100B in patients with 
mild or moderate head injury.  Although 49% of the patients had abnormal S100B 
values, 70% of the CT scans were normal. Thus, a significant number of subjects 
with high S100B values had normal CT scans (24).   They did not demonstrate any 
relationship between the level of S100B and extracranial injuries, such as long bone 
fractures. 
 In order to explore the failure of CT to visualize subtle ICI, Akhtar et al. 
examined the relationship between high S100B levels and MRI scans in children 
with traumatic brain injury and negative CT scans (25).  The authors wished to  
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determine how often both MRI and S100B were abnormal in pediatric patients with 
negative CT scans.  Seventeen children between the ages of 5 and 18 years were  
enrolled in the study.   Blood was drawn 6 hours and 12 hours after admission to the 
Emergency Department.  Akhtar et al. determined that 41% of patients with negative 
CT scans had identifiable lesions on MRI.  There was no difference in S100B 
concentrations between children with positive and negative MRI, although 
concentrations were abnormally elevated in both cases (25).  Furthermore, S100B 
concentrations were higher at both time intervals in children with head and other 
bodily injuries compared with patients who had sustained only head injury.   This 
result indicates that the principal extracranial sources of S100B, chondrocytes and 
adipocytes, when traumatized, likely release S100B into the bloodstream, and must 
be carefully considered in future studies.   
We sought to determine whether S100B could serve as a diagnostic marker of 
ICI in children.  As a result we designed a prospective study in a large cohort of 
children to establish whether serum levels of S100B in children with CHT could 
accurately predict which children would likely have ICI, as detected by CT scan.  
We hypothesized that mean serum S100B levels would be higher in children with an 
abnormal CT scan when compared to patients with unremarkable CT scans.  Our 
study would improve on previous studies in that we would evaluate a larger cohort of 
patients with CHT, examine the relationship of S100B and the presence of 
extracranial injuries, such as long bone fractures, as well as the relationship of 
S100B to the time after injury when venipuncture was performed to obtained serum  
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for analysis.  We would also evaluate how clinical symptoms after injury, such as 
loss of consciousness (LOC), headache and vomiting, and how clinical signs, such as 
the presence of altered mental status, as determined by a patient’s GCS, affect serum 
levels of S100B.  A serologic diagnostic marker, such as S100B, would be a very 
useful clinical tool for Emergency Department physicians to assess which children 
with CHT should undergo diagnostic imaging and possibly sedation, and which 
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Material and Methods 
 
 
At the Pediatric Emergency Department of Yale-New Haven Children's 
Hospital, 350 children per year less than 18 years old require CT for evaluation of 
CHT.  Of this sample, 15% have ICI.  With a two-sided 0.05 significance level, 
group sizes of 15(+ICI) and 135 (-ICI) will provide 80% power to observe a three-
fold increase in the level of S100B in the (+) ICI group compared to the (-) ICI 
group.  
All children who presented to the Emergency Department within six hours of 
closed head injury, and required a CT scan, were eligible for enrollment in the study.  
Exclusion criteria were history of seizure within seven days prior to sustaining head 
injury, penetrating head injury, encephalopathy, pre-existing developmental delay, 
Down syndrome, cerebral palsy, renal insufficiency, or intravascular hemolysis. 
 Written informed consent was obtained from the parent or guardian. We 
utilized a standardized data entry sheet to enroll each patient, recording the medical 
record number, mechanism and date of injury, initial Glasgow Coma Scale, presence 
of post-traumatic complaints, presence of intracranial injury or skull fracture on CT 
scan, existence of extra-cranial injuries (bone fractures, abdominal injuries), and the 
need for inpatient admission.  The following post-traumatic complaints were noted at 
the time of admission: headache, nausea, vomiting, loss of consciousness, dizziness, 
and altered mental status.  Injury severity was classified as mild (GCS 13-15),  
   14
 
moderate (GCS 9-12) or severe (GCS ≤ 8).  Every child who was enrolled in the 
study underwent a CT scan to exclude intracranial injury.  An attending radiologist 
as well as an attending pediatric neurosurgeon provided the final interpretation of 
each CT scan.  
 A patient’s medical record was reviewed if he/she was admitted to the 
hospital from the Pediatric Emergency Department for the treatment of traumatic 
brain injury.  The following data were noted: admission to the pediatric intensive 
care unit, need for surgical intervention, need for medical intervention, and number 
of days of hospitalization.  
 In order to measure S100B levels, venous blood samples were obtained from 
each enrolled patient in the Emergency Department within six hours of closed head 
trauma.  Blood was allowed to clot for 30 minutes, and was subsequently centrifuged 
(800-1000 RPM for 10 minutes) within six hours.  Serum samples were frozen at  -
20 °C until further analysis, at which point S100B concentrations were measured 
using an immunoluminometric assay.  Sangtec 100 (Can Ag Diagnostics AB, 
Gothenburg, Sweden) is an enzyme-linked immunoassay designed to detect the level 
of S100B in serum.  Standard and control reagents, as well as wash buffer, are 
reconstituted with de-ionized water.  Fifty µL each of standard, control reagent, and 
patient sample were pipetted into test wells.  One hundred fifty µL of tracer was 
added to the wells and incubated for 2 hours.  After washing the wells with buffer, 
100 µL of TMB substrate was added to each well.  The samples were incubated on a  
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plate shaker at 800 RPM for 15 minutes at room temperature.  The reaction was 
stopped by adding 100 µL of TMB stop solution.  The absorbance of each well was 
read over a 15-minute period at 450 nm using a microplate reader.   
Serum S100B levels were calculated for ten control subjects without closed 
head injury, 128 children with closed head injury and normal cranial CT scans, and 
24 children with closed head injury and abnormal CT scans.  We calculated an 
independent sample t-test to compare the mean level of serum S100B between 
children with ICI as detected by CT, and children without ICI.  In addition, analysis 
of covariance was utilized to adjust for group differences, such as age, race, and 
gender. Descriptive statistics were used to determine the assumptions required for 
these tests, and necessary transformations or non-parametric tests were performed to 
meet testing assumptions.  In addition, we evaluated the best combination of 
sensitivity and specificity for a particular level of S100B, in order to differentiate 
between those subjects with a positive from those with a negative scan by using the 




















Between April 2005 and October 2006, 466 children with closed head trauma 
(CHT) were evaluated at the Pediatric Emergency Department of Yale-New Haven 
Children's Hospital. One hundred fifty-two children (33%) were prospectively 
enrolled: 24 with ICI as detected by CT scan, and 128 children without ICI.  There 
were no significant differences between the two groups with respect to age, gender, 
or race (Table 1).  Injury mechanisms included falls (42%), pedestrians struck by 
vehicle (23%), motor vehicle crashes (13%), and sports collisions (9%).  Twenty-
five children had long bone fractures.  None of the children with ICI required 
operative intervention, and all were discharged to home after hospitalization. 
 Time of venipuncture after injury was significantly later in children with 
intracranial injury (62% with ICI vs. 34% without ICI; p=0.03).  Mean S100B levels 
were significantly greater in children with intracranial injury (0.213 µg/L vs. 0.0844 
µg/L; p=0.0001), in children with fractures (0.220 µg/L vs. 0.0832 µg/L; p<0.001), 
and in children who were non-white (0.127 µg/L vs. 0.0805 µg/L; p=0.03) (Table 1). 
After controlling for time of venipuncture, fractures, and race, mean S100B levels 
were still greater in children with intracranial injury (0.409 µg/L vs. 0.118 µg/L; 
p=0.0001) (Table 2).  The discriminatory value of S100B to detect closed head 
injuries (AUC) was 0.67.  When 0.050 µg/L of S100B was chosen as the cut-off 
value, sensitivity was 75%, specificity 56%, positive predictive value 20% and  
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negative predictive value was 90%.  After patients with long bone fractures were 
excluded, however, the discriminatory value increased to 0.69.  The sensitivity 
became 73%, specificity 52%, positive predictive value 23%, and the negative 
predictive value was 89%.  
There were no significant differences between the two groups with respect to 
loss of consciousness, vomiting, or amnesia following CHT.  The group of children 
who suffered an intracranial injury as diagnosed by CT scan, however, was 
significantly more likely to have a palpable scalp hematoma and a GCS < 12 in the 
Emergency Department (Table 3).   Children without ICI were significantly more 
likely to complain of headache following the CHT.  
 
 
        Patient Demographics 
 Age 
(Years) 
% Male % Caucasian % Fractures Blood Draw 
> 120 
Minutes 
(+) ICI 6.9 58% 63% 24% 62% 
(-) ICI 9.8 71% 54% 23% 34% 
P value 0.01 Not significant Not significant Not significant 0.03 
 
Table 1.  There were no significant differences between the two groups with respect 
to age, gender, or race.  Time of venipuncture after injury was significantly later in 
children with intracranial injury (p=0.03). 
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Mean S100B Levels (µg/L) 
 ICI as detected 
by CT scan 






















P value 0.001 0.03 0.008 0.001 
 
Table 2.  Mean S100B levels were significantly greater in children with intracranial 




Post-traumatic Brain Injury Complaints 
 LOC Hematoma Headache Vomiting Amnesia GCS < 12 
(+) ICI 50% 91% 24% 29% 17% 29% 
(-) ICI 55% 51% 48% 17% 27% 2% 
P value NS 0.001 0.05 NS NS 0.001 
 
Table 3.  There were no significant differences between the two groups with respect 
to loss of consciousness, vomiting, or amnesia following closed head trauma.  The 
group of children who suffered an intracranial injury as diagnosed by CT scan, 
however, was significantly more likely to have a hematoma, and a GCS < 12 in the 











The majority of children who present to the Emergency Department with 
closed head trauma (CHT) will not have intracranial injury (ICI) (23).  We wished to 
determine whether serum S100B levels could be utilized to predict the presence of 
ICI after CHT by CT scan.  A serologic assay could help to decide which children 
CHT would most likely benefit from diagnostic imaging to exclude ICI.  While we 
found that mean serum levels of S100B are higher in children with ICI than those 
without ICI, the discriminatory value of S100B to detect ICI was only 0.67.  Thus, 
S100B may not be an accurate screening tool to detect ICI in children after CHT. 
There are both strengths and weaknesses of this study.  The strengths include 
large sample size (152 children), and a diverse spectrum of injury mechanisms (falls, 
motor vehicle accidents, sports).  Also, there were no significant differences between 
the two groups (with and without ICI) with respect to age, gender, or race. 
Weaknesses include the short half-life of S100B, a characteristic that, in retrospect, 
does not make it a useful screening tool for ICI in children who present for medical 
evaluation more than six hours after CHT.  A number of our subjects with ICI 
arrived at Yale-New Haven Children’s Hospital after having been referred from 
smaller hospitals, thus increasing the time between injury and venipuncture, and may 
have had lower levels of S100B, thus reducing the ability of S100B to detect ICI in 
this group of children.  
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In this study, children with both ICI and long bone fractures had significantly 
higher S100B levels than those without.  Our results in children differ from data 
compiled by Berger, who did not find that serum levels of S100B were affected by 
the presence of fractures.  Our results suggest that extra-cerebral sources of S100B, 
such as that from long bone fractures, affect the specificity of S100B to detect ICI.  
Two studies in the adult population have evaluated the relevance of extra-
cerebral sources of S100B in the setting of ICI.  Unden et al. examined S100B levels 
after uncomplicated bone fractures in adult patients without neurological disease. 
Blood was drawn from 55 adults who presented to the Emergency Department with 
orthopedic fractures no older than 24 hours (26).   Patients with head injury were 
excluded from this study.  S100B values of greater than 0.150 µg/L were considered 
elevated.  Twenty-nine percent of subjects had S100B values above that cut-off 
value.  The authors determined that patients with hip, tibia, and radial fractures were 
more likely to have high S100B values than those with smaller fractures to hands or 
feet (26).   Had Unden et al. chosen a lower cut-off value, such as 0.050 µg/L 
(utilized in our study), they would have had many more subjects with elevated 
S100B values in the setting of orthopedic fractures.  Although S100B could function 
as a marker of brain injury, the existence of extra-cerebral sources of S100B makes it 
difficult to interpret an elevated S100B value in a patient with both ICI and bone 
fractures.   
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Savola et al. studied the S100B values of 224 adults with head trauma (mild, 
moderate, or severe), and 155 adults with an assortment of extra-cranial injuries, 
including soft tissue contusions, sprains, and small and large fractures (27).  Patients 
with head trauma had significantly higher median S100B values (0.170 µg/L) than 
patients with extra-cranial injuries (0.070 µg/L).  Furthermore, serum S100B values 
correlated with the severity of brain injury; individuals with severe brain trauma had 
higher values of S100B than patients with mild or moderate ICI.  Savola et al. also 
noted that extra-cranial injury independently increased S100B levels (27).   Soft 
tissue contusions, sprains, luxations, and small fractures led to mildly elevated 
S100B levels in only 3% of patients.  Large fractures and abdominal injuries that 
were obtained in the absence of brain injury, however, significantly increased S100B 
values, suggesting that large extra-cranial injuries may decrease the positive 
predictive value of S100B as a diagnostic marker of brain trauma in patients with 
multiple injuries.  At present, other than this current study, there has been no other 
study to evaluate the effect of extra-cranial injury on the serum levels of S100B in 
children with CHT. 
 Of our sample of 152 patients with CHT, 24 children (16%) had ICI by CT. 
One may argue that MRI would have revealed a larger number of traumatic lesions 
than did CT alone.  Thus, we may have mistakenly categorized children with brain 
injury undetectable by CT scan, but potentially visible on MRI, in the group of  
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children without ICI. If such patients with ICI detected only by MRI had elevated 
S100B levels, such an error would falsely elevate the mean S100B value of the group  
without ICI as detected by CT alone, thus narrowing the statistical difference 
between the two groups. Akhtar et al. examined 17 children between 5-18 years of 
age who presented to the Emergency Department with traumatic brain injury and had 
a negative CT scan (25).   Patients subsequently underwent a standard non-contrast 
MRI with added FLAIR and GRE sequences.  S100B values for each patient were 
also recorded.  Forty-one percent of patients with a negative CT scan had positive 
findings on MRI, emphasizing the superior sensitivity of MRI in recognizing subtle 
ICI.  All brain lesions were visible on FLAIR sequence, and 77% of lesions were 
visible on axial T-2 images.  Although S100B levels were elevated, there was no 
significant difference in S100B concentrations when children with positive MRI 
findings were compared to those with unremarkable MRI scans (25).  The use of 
MRI in the Emergency Department setting is impractical, given the time needed to 
complete the study and the requirement for sedation to render the young patients 
motionless.  It is also important to note that none of the patients in our study who had 
ICI as detected by CT alone, and those in Ahktar's study with ICI as detected by 
MRI alone, required operative intervention for ICI.  While the development and use 
of "quick-brain" MRI in the Emergency Department would make the detection of ICI 
in children with CHT easier, its use is not likely in the Emergency Department 
setting in the near future. 
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 While S100B may not be a reliable screening tool for ICI in children after 
CHT, it may serve as a prognostic tool for outcome after ICI.  Currently a patient’s  
Glasgow Coma Scale (GCS) is utilized to help predict his or her ability to recover 
neurological function after traumatic brain injury.  Feickert et al. examined the 
relationship between ICI and GCS in pediatric patients (28).   In this retrospective 
study, 150 children with traumatic brain injury and initial GCS ≤ 8, who were treated 
in the pediatric intensive care unit, were enrolled.  All patients underwent CT scans; 
43.3% had a head fracture and 57.9% were diagnosed with an ICI.  Low GCS was 
highly predictive of poor neurological outcome.  The likelihood of survival for 
patients with GCS < 5 was 0.18 compared with 0.94 for patients with GCS ≤ 8 to 5 
(p < 0.0001) (28).   Similarly, in our study, the group of children who suffered an ICI 
as diagnosed by CT scan was significantly more likely to have a GCS < 12 in the 
Emergency Department.  If S100B levels correlate with GCS, one may argue that 
patients with ICI who also have high S100B levels will likely have a worse 
neurological prognosis than patients with lower S100B values.  Herrmann et al. 
analyzed S100B levels in the first three days after traumatic brain injury in 69 
patients between the ages of 16 and 65 years (29).  GCS were obtained in the 
Emergency Department and ten days after traumatic brain injury. Comprehensive 
neuropsychological testing was performed in 39 patients two weeks after hospital 
admission and in 29 patients approximately 6 months after traumatic brain injury.  
Initial S100B levels greater than 0.140 µg/L had the highest predictive power of  
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short and long-term neuropsychological disorders.  Thus, S100B could serve in 
conjunction with GCS as a predictive marker of long-term neurological outcome 























 After controlling for time of venipuncture, fractures, and race, S100B levels 
were higher in children with ICI than those without such injury.  However, the 
discriminatory value used to detect S100B was only 0.67.  This study demonstrates 
that S100B may not be a practical screening device of ICI in children who present to 
the Emergency Department with CHT.  The short half-life of the protein, combined 
with its higher average value in non-Caucasian children than in age-matched 
Caucasian counterparts, and its higher numeric value in children with bone fractures, 
do not make S100B a sensitive or specific biologic marker of ICI in children. 
Additional study of S100B is necessary in order to determine whether it can serve as 
a useful adjunct to evaluate children for intracranial injury CHT.  Future evaluation 
of S100B in children with CHT and ICI may demonstrate its usefulness in predicting 
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